ASTRAZENECA PLC

How analyst target‑price shifts reveal AstraZeneca’s growth prospects amid patent cliffs, pricing pressure, and strategic M&A plans.

Explore how value‑based reimbursement, bundled payments, and AI tech reshape UK healthcare finance, workforce, and patient equity for higher margins and better outcomes.

AstraZeneca’s share price plunged 10% after its Wainua cardiovascular trial failed, but analysts note a resilient pipeline and M&A plans that could offset the loss.

Analyze AstraZeneca’s Wainua phase‑III failure and uncover how pricing, competition and M&A can reshape its ATTR strategy and protect future profits.

Explore why AstraZeneca stands out in Europe’s diversified equity scene, balancing a strong drug pipeline, patent cliffs and M&A buzz to shape investor outlook.

Enhertu’s new EMA approval expands AstraZeneca’s HER2‑positive market, while Datroway gains European access, boosting oncology reach and shareholder confidence.

AstazeroZeneca shares dip amid market volatility but maintain solid fundamentals; discover how regulatory shifts and personalized medicine can drive future growth.

Explore how AstraZeneca’s AI‑driven discovery, Ultomiris’s Phase III breakthrough, and patient‑engagement strategies reshape market access and boost shareholder value.

Shares of AstraZeneca dipped in London, but the company’s mixed performance hinges on strong clinical data—especially SERENA‑6 results—highlighting its oncology pipeline’s potential, making investors watch closely for regulatory moves that could res…

FDA extends AstraZeneca’s camizestrant review, boosting its chance in advanced breast‑cancer treatment with ctDNA data, value‑based pricing, and global rollout plans.